A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

Exclusion Criteria

• •1. Known CNS primary tumor and active or untreated CNS metastases
• •2. History of another primary malignancy that has been diagnosed or required therapy within the past 2 years
• •3. Toxicities of prior therapy have not been resolved to ≤ Grade 1 or to baseline
• •4. Significant cardiovascular disease, including congestive heart failure
• •5. Known hepatitis B, hepatitis C, or human immunodeficiency virus infection that is active
• •6. Have a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.